Literature DB >> 2655528

Structure-activity relationships of the fluoroquinolones.

D T Chu1, P B Fernandes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2655528      PMCID： PMC171443          DOI： 10.1128/AAC.33.2.131

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  40 in total

1.  Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Authors:  A Sugino; C L Peebles; K N Kreuzer; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

Review 2.  Development of antibacterial agents of the nalidixic acid type.

Authors:  R Albrecht
Journal:  Prog Drug Res       Date:  1977

3.  Studies on chemotherapeutic agents. I. Synthesis of quinoline and naphthyridine sulfonamide or phosphonic acid derivatives.

Authors:  H Yanagisawa; H Nakao; A Ando
Journal:  Chem Pharm Bull (Tokyo)       Date:  1973-05       Impact factor: 1.645

Review 4.  DNA gyrase and the supercoiling of DNA.

Authors:  N R Cozzarelli
Journal:  Science       Date:  1980-02-29       Impact factor: 47.728

5.  Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.

Authors:  H Koga; A Itoh; S Murayama; S Suzue; T Irikura
Journal:  J Med Chem       Date:  1980-12       Impact factor: 7.446

6.  Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.

Authors:  D Gargallo; M Moros; R Coll; M Esteve; J Parés; M A Xicota; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

7.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

8.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  [A new synthetic antibacterial : 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin-3-carboxylic acid (1589 R.B.)].

Authors:  Y Goueffon; G Montay; F Roquet; M Pesson
Journal:  C R Seances Acad Sci III       Date:  1981-01-05
View more
  56 in total

1.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

3.  Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.

Authors:  Chengxin Zhi; Zheng-Yu Long; Andrzej Manikowski; Jeanne Comstock; Wei-Chu Xu; Neal C Brown; Paul M Tarantino; Karsten A Holm; Edward J Dix; George E Wright; Marjorie H Barnes; Michelle M Butler; Kimberly A Foster; William A LaMarr; Benoit Bachand; Richard Bethell; Caroline Cadilhac; Sylvie Charron; Serge Lamothe; Irina Motorina; Richard Storer
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

4.  Oxidation of ofloxacin by Oxone/Co(2+): identification of reaction products and pathways.

Authors:  Yunqing Pi; Jinglan Feng; Jingyu Sun; Mengke Song; Jianhui Sun
Journal:  Environ Sci Pollut Res Int       Date:  2013-11-01       Impact factor: 4.223

Review 5.  Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.

Authors:  T D Gootz; J F Barrett; J A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

6.  Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics.

Authors:  J D Vrany; P S Stewart; P A Suci
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck.

Authors:  L Intorre; G Mengozzi; S Bertini; M Bagliacca; E Luchetti; G Soldani
Journal:  Vet Res Commun       Date:  1997-02       Impact factor: 2.459

8.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

9.  Value of new quinolones in the treatment and prophylaxis of infectious diseases: introductory remarks.

Authors:  J S Wolfson; B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

10.  An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.

Authors:  Elena K Schneider; Mohammad A K Azad; Mei-Ling Han; Qi Tony Zhou; Jiping Wang; Johnny X Huang; Matthew A Cooper; Yohei Doi; Mark A Baker; Phillip J Bergen; Mark T Muller; Jian Li; Tony Velkov
Journal:  ACS Infect Dis       Date:  2016-05-17       Impact factor: 5.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.